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Multiple myeloma (MM) represents a B cell malignancy, charac-
terised by a monoclonal proliferation of malignant plasma cells
(Ludwig et al, 1999). During the main course of disease evolution,
terminally differentiated B cells preferentially accumulate in the
bone marrow (BM) and represent the main cell type. However,
several studies indicated that the tumour clone also includes circu-
lating B cells that might represent the ‘myeloma stem cell’. Clear
evidence supporting this statement was provided by molecular
techniques showing that MM patients have B cells in circulation
harbouring the same immunoglobulin (Ig) gene rearrangements as
the malignant BM plasma cells (Van Riet et al, 1989). Moreover it
was demonstrated that these circulating MM cells show in their Ig
genes the presence of somatic mutations without intraclonal varia-
tion (Bakkus et al, 1992). This implicates that MM originates from
a B cell that has been antigen-selected in the germinal centre of the
lymph node. The restricted localisation of MM cells in the BM
during the initial stage of disease could be explained by a selective
initial homing of circulating MM cells to the BM microenviron-
ment and/or by the presence of a unique combination of survival
and growth factors provided by the BM microenvironment not
present in other tissues (Van Riet et al, 1998; Vanderkerken et al,
2000). 
In analogy to the migration mechanisms used by normal leuko-
cytes and metastatic carcinoma cells (Liotta, 1986; Butcher and
Picker, 1996), the migration of MM cells to the BM is likely to be
mediated by similar mechanisms. During lymphocyte homing and
tumour cell invasion, cells attach to and degrade components of
the extracellular matrix (ECM) before passing through. Previous
studies already revealed the importance of interactions of malig-
nant cells with the basement membrane during invasion. The base-
ment membrane represents a specialised form of ECM, which
separates the endothelium from the underlying interstitial stroma.
It is composed of several components including collagen IV,
glycoproteins such as laminin, fibronectin and proteoglycans
(Vracko, 1974). Components of the ECM, including laminin,
fibronectin and type IV collagen, as well as their proteolytic diges-
tion products have been shown to stimulate the in vitro migration
of a variety of normal and malignant cell types (Klominek et al,
1993). Laminin-1 (LN), a well characterised cell adhesion protein,
represents the major non-collagenous glycoprotein of the base-
ment membrane, involved in multiple important biological activi-
ties such as cell adhesion, migration, spreading, proliferation,
growth and differentiation (Malinda and Kleinman, 1996). Very
recently, Spessotto et al (2001) have demonstrated that different
LN isoforms may evoke diverse cellular responses in different
neoplastic lymphocytes. Invasion of the subendothelial basement
membrane is mediated in part by interactions of tumour cells with
laminin via specific cell surface receptors (Ramos et al, 1991). The
67 kD laminin-binding protein (67LR) represents a non-
integrin-binding protein which binds LN with high affinity
(Malinoff and Wicha, 1983). Expression of 67LR has been shown
to be increased in neoplastic cells as compared to their normal
counterparts and directly correlates with an enhanced invasive and
metastatic potential (D’Errico et al, 1991; Kim et al, 1998).
Additionally, suppression of the expression of the precursor of
67LR (37LBP) with antisense 37LBP/p40 RNA using a retroviral
vector reduces the capability of lung cancer cell proliferation in
vitro and tumour formation in vivo (Satoh et al, 1999), clearly
indicating the role of 67LR in tumorigenicity. 
In the present study, we demonstrated that MM cells express
the 67 kD high-affinity LN receptor. In addition, we found
that LN acts as a chemoattractant for MM cells by binding to
67LR. 
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the B1 chain of LN. MM cell migration was partially blocked by peptide 11, a synthetic nonapeptide derived from this amino sequence and also
by a blocking antiserum against 67LR. Co-injection of peptide 11 with 5T2MM cells in a murine in vivo model of MM resulted in a decreased
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Human MM cell lines (HMCL) 
Three well characterised HMCL (MM5.1, MMS.1 and U266)
were selected for our experiments. They were cultured as
described (Nilson, 1971; Okuno et al, 1991; Van Riet et al, 1997). 
Patient samples 
BM samples from 5 MM patients (pts) (age 52–94, mean 66.5;
M/F, 3/5) were collected during standard diagnostic procedures.
The study was approved by the local ethical committee. According
to Durie and Salmon’s clinical staging system (1975), patients
were distributed as follows: stage I, 1 pt; stage II, 2 pts; stage III, 2
pts. BM aspirates were collected in a heparinised syringe.
Mononuclear cells were separated by density gradient centrifuga-
tion over Ficoll-Hypaque (Life Technologies). 
MACS separation of primary MM cells 
Primary MM cells expressing the CD138 antigen were immuno-
magnetically separated using the Magnetic Cell Sorting System
(MACS) (Miltenyi Biotech). Cells were incubated for 15 minutes
at 4˚C with MACS microbeads conjugated to a monoclonal mouse
CD138 (syndecan-1) antibody (clone B-B4, isotype mouse IgG1)
(40 µ l 107 cells). Cells were washed once in PBS supplemented
with human albumin (4%), resuspended and separated on a
column placed in the magnetic field of the MACS separator.
CD138+ cells were retained in the column and eluted as positively
selected cell fraction after removal of the column from the
magnetic field. Cells were counted and viability was assessed with
trypan blue. MACS purification produced a ≥ 97% pure prepara-
tion. 
5T2 murine MM model 
Male C57B1/KaLwRijHsd mice, 6–10 weeks old were purchased
from Harlan CPB. Mice were housed under conventional condi-
tions and fed ad libitum (license number LA 1230281). 5T2MM
cells originated spontaneously in aging mice (Radl et al, 1979).
The 5T2MM model displays characteristics analogous to human
MM (Asosingh et al, 2000). Cells were prepared as described
previously (Vanderkerken et al, 1997). Briefly, cells were obtained
by flushing the BM of hind legs. Cells were purified by gradient
centrifugation on lymphocyte M (Cedarlane), washed and purified
by Percoll (Pharmacia AB) gradient centrifugation. Cell purity
(> 90%) was verified by FACS staining with 5T2MM anti-idio-
type specific antibodies (Vanderkerken et al, 1997). 5T2MM cells
were used for in vitro and in vivo experimental assays. 
Peptides 
LN, extracted and purified by immunoaffinity from the
Engelbreth-Holm-Swarm (EHS) tumour was purchased from
Sigma-Aldrich and peptide 11, a synthetic nonapeptide derived
from the B1 chain of LN was purchased from Eurobiochem. A
control scrambled nonapeptide (Ala-Asp-Cys-Gly-Gly-Ile-Pro-
Ser-Tyr) was purchased from Genosys. 
RNA extraction and Northern blotting 
Northern blot hybridisation has been used to assess the expres-
sion of mRNA for the 37 kD precursor of 67LR from total RNA
extracts from cultured HMCL. The plasmid DNA which carries
the cDNA for the 37 kD precursor of 67LR (a kind gift from Dr
Vincent Castronovo, Mestastasis Research Laboratory, Uni-
versity of Liege, Belgium) was digested with XbaI. The released
fragment was purified using the Wizard DNA clean up purifica-
tion kit (Promega). Total RNA was isolated from cultured
HMCL with the RNeasy Mini Kit (Qiagen). For Northern blot
analysis, equal amounts of total RNA (10 µ g) were denatured
with 37% formaldehyde and deionised formamide, subsequently
separated through a 1% agarose-formaldehyde gel and blotted
onto Biobond nylon membranes (Sigma-Aldrich). cDNA probes
encoding for the 37 kD precursor of 67LR were radioactively
labelled with 32P-dCTP. Prehybridisation was performed in 50%
formamide, 5 × Denhardt’s solution, 2 × SSC, 1% SDS and
100 mg ml–1 denatured salmon sperm DNA for 3 hours at 42˚C.
Blots were subsequently hybridised overnight at 42˚C. After
hybridisation, membranes were stringently washed by vigorous
rotation at 42˚C for respectively 5, and 2 × 30 minutes in each of
the following solutions: 2 × SSC/0.1% SDS and 0.2 × SSC/0.1%
SDS. After washing, membranes were exposed to film (Kodak
Biomax MR) overnight at –80˚C. As a control for the quality and
quantity of the RNA samples analysed, the same blots were
hybridised with a glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA probe. The blotting experiment was repeated
twice with different RNA preparations. 
Flow cytometric analyses 
Fluorescence-activated cell sorting (FACS) analyses were
performed to characterise the expression of 67LR on HMCL.
After washing, cells were incubated with a monoclonal antibody
(MLuC5) (IgM) recognising 67LR (kindly provided by Dr V
Castronovo, Metastasis Research Laboratory, University of
Liege, Belgium) and a polyclonal rabbit antiserum against 67LR
(provided by Dr HK Kleinman, Institute of Dental and
Craniofacial Research, National Institute of Health, Bethesda,
USA). The last mentioned antiserum was also used to demon-
strate 67LR expression on the murine 5T2MM cell line. As nega-
tive control, cells were incubated with isotype-matched
irrelevant mouse Ig or rabbit Ig antibodies. Cells were subse-
quently washed in PBS/BSA and incubated with rabbit anti-
mouse Ig antiserum or swine anti-rabbit Ig antiserum, both
conjugated with fluorescein isothiocyanate (FITC) (Dako). Next,
cells were washed, resuspended in PBS/BSA and finally
analysed by flow cytometry (EPICS XL, Coulter Electronics).
67LR expression on MM plasma cells from patient samples was
evaluated by a double staining procedure. Mononuclear cells
isolated by Ficoll centrifugation were incubated with the MLuC5
monoclonal antibody as indicated above. After washing, cells
were simultaneously incubated with a PE conjugated goat anti-
mouse IgM antiserum (Southern Biotechnology) and a Cy-5-
conjugated CD38 specific antibody (HIT2) (BD Pharmingen).
Plasma cell identification was controlled by co-expression of
CD38 and intracytoplasmic κ /λ immunofluorescence using
three-colour staining (rabbit anti-human Igκ -FITC and Igλ -PE
F(ab)2 fragments (Dako)). 
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line 
In order to evaluate whether the expression of 67LR on MM
plasma cells could be modulated by exposure to endothelial cells,
mononuclear cells isolated from MM BM samples were co-
cultured for 24 hours with the BM endothelial cell line 4LHBMEC
(kindly provided by Dr A Dräger, Department of Hematology,
Free University Amsterdam, The Netherlands). This cell line was
cultured in 10% FCS medium 199 with 10 ng ml–1 ECGF (Roche)
until a confluent adherent mono cell layer was obtained.
Mononuclear cells were incubated at 106 cells ml–1 in 5% FCS-
RPMI with or without pre-established confluent monolayers of
4LHBMEC. After 24 hours non-adherent cells were removed by
gentle pipeting and FACS analysis was performed. 
In vitro cell migration assays 
We performed in vitro migration assays with murine and human
MM cells using an in vitro Transwell® cell migration system
(Costar Corning) with 5 and 8 µ m pore size membrane filters
respectively. MM cells (1 × 105) were added to the upper well in
100 µ l medium. LN was diluted in 300 µ l RPMI 1640 medium in
varying concentrations and added to lower wells. Cells were tested
for their spontaneous motility in response to control medium
(RPMI 1640). The migration responses to LN were tested with
controls in the same assay. After an incubation of 3 hours at 37˚C
in a humidified 5% CO2 atmosphere, the number of cells that
migrated through the filter into lower wells was quantified with a
non-radioactive, colorimetric assay system using XTT (Roche)
(Roehm et al, 1991). XTT with phenazine methosulfate (PMS)
was added in each well after removal of inserts and incubated for
5 hours at 37˚C. The absorbance of converted stain was measured
spectrophotometrically with a 96-well microplate reader (Ceres
900 Bio-Tek International Inc) at a wavelength of 450 nm with a
reference wavelength of 650 nm. Migration responses were deter-
mined as the percentage increase in cell migration compared to
spontaneous migration. All experiments were performed in tripli-
cate. Zigmund–Hirsh checkerboard analysis (Zigmund and Hirsch,
1973) was performed to distinguish chemokinesis from chemo-
taxis. For migration-inhibition experiments, MM cells were incu-
bated with peptide 11 or with a blocking polyclonal antiserum
directed against 67LR (Clement et al, 1990). Scrambled peptide 11
and a polyclonal rabbit IgG (Chemicon International) served as
controls. LN was used at 50 µ g ml–1. Migration responses were
compared with control migration to LN and determined as
described above. 
For transendothelial migration, 2 × 105 endothelial cells
(4LHBMEC) were seeded on TranswellR filters. Confluent mono-
layers were formed after two days. Freshly isolated primary MM
cells (1 × 105) were added to the upper compartment of the
TranswellR system, with or without peptide 11 (50 µ g ml–1), and
allowed to migrate overnight. LN (50 µ g ml–1) was added as
chemoattractant to the lower compartment. Transmigrated MM cells
were recovered and counted by flow cytometry (FACSort, Becton
Dickinson). Migration responses were determined as described. 
In vivo experimental assays 
For in vivo experiments, 5T2MM cells were labelled with 500 µ Ci
51Cr-chromate (Amersham). After washing, cell viability was
assessed by trypan blue exclusion and cells were resuspended in
RPMI 1640 at 2.5 × 106 ml–1. Peptide 11 or scrambled peptide 11
was solubilised at 2 mg ml–1 in PBS and mixed with 5T2MM cells
suspensions (5 × 105) in a final volume of 200 µ l. After 5 min
incubation, 5T2MM cells were co-injected with peptide 11, scram-
bled peptide 11 or PBS intravenously into the tail vein of
syngeneic mice. After 18 hours, mice were killed, legs, ribs and
vertebrae were removed, subsequently rinsed in PBS and the
radioactivity was determined by gamma-counting (MR48OC/TP
ITM, Van Hopplynus) to estimate the level of tumour infiltration
in the BM (Vanderkerken et al, 2000). Control and treatment groups
each contained 9 mice.
Statistical analysis 
Statistical analyses were performed using the 2-sample t-test. A P
value of less than 0.05 was considered significant. Values were
expressed as the mean ± SD. 
RESULTS 
LN receptor expression by HMCL, murine 5T2MM cells
and fresh MM plasma cells 
To characterise the HMCL with respect to their expression of
67LR, we performed Northern blotting and flow cytometric
analysis using a specific monoclonal antibody to 67LR. Northern
blot analysis revealed a homogeneous expression of mRNA for the
37 kD precursor of 67LR in all 3 HMCL tested (Figure 1A). Flow
cytometry demonstrated the surface expression of 67LR on HMCL
and the murine 5T2MM cells (Figure 1B). 67LR expression on
CD38bright+ plasma cells from 5 MM BM samples was more weak
(Figure 1B). However, an increased expression of this receptor
could be observed after direct exposure of tumour cells to a BM
endothelial cell line (4LHBMEC) as illustrated in 3 patients
(Figure 2). 
Effect of LN on the in vitro migration of HMCL and
murine 5T2MM cells 
The migration of 3 HMCL (MM5.1, U266 and MMS.1) and the
5T2MM cells was evaluated in the presence of LN. As shown in
Figure 3, increasing concentrations of LN (10 to 100 µ g ml–1)
resulted in an increased number of cells migrating through the
microporous membrane, with a mean increased migration
response up to 90%. Checkerboard analyses revealed that MM cell
migration to LN was chemotactic with a chemokinetic component
(Table 1). 
Inhibitory effect of peptide 11 on MM cell migration to
LN 
Peptide 11 has been shown to possess the ability to inhibit the
biological activity of LN by competing for binding with 67LR.
We investigated whether peptide 11 could modulate the interac-
tions between MM cells and LN and we tested its effect on the
migration of MM5.1 and 5T2MM cells in response to LN. In
vitro cell migration assays were carried out with LN (50 µ g ml–1)
added to the lower well of the migration system. MM cells were
placed in upper wells, together with peptide 11 (10, 50 or
100 µ g ml–1) or scrambled peptide 11 (100 µ g ml-1). As shown in 
Figure 4, peptide 11 inhibited MM cell migration to LN.
Laminin-1-induced migration of multiple myeloma cells 1389
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tion of cell migration was gradually reduced. This last effect
most likely relates to the chemokinetic effect of peptide 11 (Graf
et al, 1987a). Scrambled peptide 11 did not affect in vitro MM
cell migration to LN. 
Effect of a blocking antiserum against 67LR on MM cell
migration to LN
In order to evaluate the importance of 67LR in the interaction of
MM cells with LN, we tested the effect of a blocking polyclonal
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Figure 1 Expression of 67LR on HMCL, murine 5T2MM cells and MM cells from BM samples. (A) Representative Northern blot signals to transcripts from
three HMCL show a homogeneous expression of the 37 kD precursor of 67LR in all tested HMCL. (B) Representative results of flow cytometric analysis are
shown and expressed as log fluorescence versus number of cells. Background fluorescence is represented by white histograms, 67LR expression by black
histograms. 67LR expression on malignant plasma cells from five bone marrow samples of MM patients was analysed by two-colour immunofluorescence using
CD38-Cy5 antiserum against 67LR on MM cell migration to LN. As shown in
Figure 5, antiserum against 67LR partially inhibited the migration
response induced by LN in a dose-dependent manner. 
Effect of LN and peptide 11 on the in vitro migration of
primary MM cells 
Previously, in vitro cell migration experiments to laminin were
performed using primary MM cells freshly isolated from the bone
marrow of patients with myeloma. Only minor migration
responses were observed when LN was added to the lower
compartment (data not shown). Considering the weak basal
expression of 67LR on primary MM cells and its up-regulation
when co-cultured with bone marrow endothelium, we carried out
in vitro migration assays after coating the TranswellR filters with
BM endothelial cells. In this condition, a significant migration
response was observed to LN, indicating that 67LR was up-
regulated by contact with endothelium, as found also in the co-
culture experiments. LN-induced migration of primary MM cells
could also be inhibited by peptide 11, again suggesting a role of
67LR in the observed migration responses (Fig. 6). 
Effect of peptide 11 on the in vivo migration of murine
MM cells
The 5T2MM murine model was also used to evaluate whether
treatment with peptide 11 affects the in vivo migration of tumour
cells to the BM. Therefore, we injected 51Cr-labelled 5T2MM cells
Laminin-1-induced migration of multiple myeloma cells 1391
British Journal of Cancer (2001) 85(9), 1387–1395 © 2001 Cancer Research Campaign
100
100
101
102
P
E
−
C
Y
103
104
101 102 103 104 100
100
101
102
P
E
−
C
Y
103
104
101 102 103 104
0.1
0.1
1000
P
E
−
C
Y
1000
PE
0.1
0.1
1000
P
E
−
C
Y
1000
PE
0.1
0.1
1000
P
E
−
C
Y
1000
PE
0.1
0.1
1000
P
E
−
C
Y
1000
PE
PE PE
Before co-culture After co-culture
Pt 1
Pt 2
C
D
3
8
67LR
Pt 3
1
H
2
34
1
H
2
34
1
H
2
34
1
H
2
34
Figure 2 Modulation of 67LR expression on MM plasma cells after exposure to the BM endothelial cell line 4LHBMEC. 67LR expression on malignant plasma
cells was analysed before and after co-culturing mononuclear cells from three MM bone marrow samples with the 4LHBMEC cell line. Cells were analysed by
two-colour immunofluorescence using CD38-Cy5 together with peptide 11 or scrambled peptide 11 intravenously
into the tail vein of syngeneic mice. Tumour cell infiltration in 
the BM was determined by counting the radioactivity in legs, ribs
and vertebrae after 18 hours. Results were represented as the % 
of recovered cpm in control and treated animals. As shown in
Figure 7, co-injection of 5T2MM cells with peptide 11 signifi-
cantly reduced (25%, P < 0.05) MM cell migration to the BM
compartment. Scrambled peptide 11 did not affect the in vivo MM
cell migration. 
DISCUSSION 
The homing of circulating MM cells to the BM implicates that
these cells must be equipped with appropriate cell surface recep-
tors, which allow binding to and traversing through the endothe-
lium. Very little information is available about the molecular
mechanisms used by MM cells during extravasation. Several
studies indicated that the interaction of tumour cells with compo-
nents of the ECM represents a key step in the biology of cancer
cell migration and invasion. In the present study, we focused on
the specific role of LN in MM cell migration. 3 well-characterised
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Table 1 Checkerboard analysis of MM5.1 cell migration to laminin 
% increase of  0  µ g ml– 1 10 µ g ml– 1 50 µ g ml– 1 100 µ g ml–1
control migration
0 µ g ml–1 11 1 1  
10 µ g ml–1 5 16 53 53 
50 µ g ml–1 32 36 63 73 
100 µ g ml–1 68 73 68 52 
MM5.1 cells were analysed for their motility response to different
concentrations of laminin (0–100 µ g ml–1) added to upper and lower wells of
the Transwell migration system. Each square of the ‘checkerboard’
represents a condition with a unique gradient. The number in each square
represents the cell migration in response to the given concentration of
attractant in upper and lower wells (chemotaxis). The diagonal shows the
number of cells which migrated in the absence of gradient (chemokinesis).
Migration responses are presented as the percentage increase of control
migration to RPMI. Representative results of three independent assays. 
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Figure 3 Migration of HMCL and murine 5T2MM cells in the presence of
LN. LN was tested for its ability to promote the migration of HMCL and
5T2MM cells. Increasing concentrations of LN were added to the lower wells
of the Transwell® migration system as indicated. As negative control, dilution
medium (RPMI) was added to lower wells. Columns represent the
percentage increase of control migration in the presence of various amounts
of peptide as indicated. Mean increase of control migration ± SD of 3
independent experiments is shown 
0
20
40
60
80
100
%
 
C
o
n
t
r
o
l
 
m
i
g
r
a
t
i
o
n
MM5.1 5T2MM
Peptide 11 added
0 µ g ml–1
10 µ g ml–1
50 µ g ml–1
100 µ g ml–1
Scrambled peptide
11 (100 µ g ml–1)
Figure 4 Effect of peptide 11 in inhibiting MM cell migration to LN. In vitro
cell migration assays were performed with LN added into lower wells at 
50 µ g ml–1. MM5.1 and murine 5T2MM cells were placed into upper wells,
together with various concentrations of peptide 11 or scrambled peptide 11 as
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Figure 5 Effect of a polyclonal blocking antiserum against 67LR on MM cell
migration to LN. Cell migration of 2 HMCL is shown (MM5.1 and MMS.1). LN
was used at 50 µ g ml–1. MM cells were incubated with various concentrations
of a polyclonal blocking antiserum against 67LR and a control rabbit IgG
antiserum as indicated. Controls were incubated without antisera. Inhibition is
represented as the mean percentage of cell migration (± SD) compared to
control MM cell migration (100%) towards LN. Experiments were repeated
twice HMCL, as well as the murine 5T2MM cell line were selected for
our experiments. The expression of 67LR, a high-affinity LN-
binding protein, was analysed by Northern blotting and FACS
analysis. All human MM cell lines and the murine 5T2MM cells
expressed 67LR. 67LR is expressed by several normal cell types,
as well as cancer cells of different origin, including B cell
lymphoma (Carbone et al, 1995), but its expression on MM cells
has not been reported so far. In vitro migration experiments
demonstrated that LN stimulated the chemotactic migration of
HMCL and murine 5T2MM cells. Previous studies revealed that
the action of LN appeared through binding to 67LR with a
sequence of 9 amino acids Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg
(CDPGYIGSR) (Situ et al, 1984). A synthetic nonapeptide
(peptide 11), derived from this aminosequence was found to be
able to compete with LN for binding to 67LR (Graf et al, 1987b).
In vivo, it reduces the formation of experimental lung and oste-
olytic metastasis (Iwamoto et al, 1987, 1996; Nakai et al, 1992)
and inhibits human pre-B leukaemic cell growth and dissemination
to organs in SCID (Yoshida et al, 1999). We evaluated the effect of
this synthetic nonapeptide on MM cell migration and observed that
peptide 11 reduced MM cell migration to LN. In addition, we
could demonstrate that the migration of MM cells could be inhib-
ited by a blocking polyclonal antiserum against 67LR (Clement 
et al, 1990). These data allow us to conclude that 67LR plays an
important role in the motility-promoting activity of LN on MM
cells. The polyclonal antiserum against 67LR could not induce a
complete inhibition of MM cell migration to LN indicating that
other receptors might influence this motility process as well. In a
previous study, Shibayama et al (1995) demonstrated that the
migration of 2 HMCL (FR4ds and OPM-1 ds) to LN could be
partially inhibited by a blocking antibody against the common
chain of β 1 integrins. This may indicate that the overall migration
of MM cells to LN might be mediated by multiple receptors.
Freshly isolated MM plasma cells from patient BM samples were
also found to express 67LR but at a much lower level.
Interestingly, 67LR expression could be enhanced when primary
MM cells were co-cultured with a human BM endothelial cell line,
whereas 67LR expression remained unchanged after contact with
BM stromal fibroblasts (data not shown). Moreover, in vitro
migration experiments with primary MM cells revealed an
enhanced migration response to laminin when TranswellR filters of
the migration system were coated with endothelial cells. This
could indicate that 67LR is temporally up-regulated at the moment
that MM cells adhere to and migrate through the endothelium
while receptor expression decreases when tumour cells reside as
fully matured plasma cells in the BM compartment. Accordingly,
HMCL might express more 67LR because they reflect a more
immature tumour stage than fully matured plasma cells. It was
demonstrated that 67LR was co-localised with alpha-actin and
vinculin, 2 structural cell proteins (Massia et al, 1993) suggesting a
direct role for 67LR in cell motility. 
To determine at which level LN-67LR interactions also influ-
ence the in vivo homing of MM cells, we used the murine 5T2MM
model. This model has been intensively characterised and was
found to express very similar pathological and biological features
as human MM (Vanderkerken et al, 1996, 1997). In a recent study,
we could demonstrate that 5T2MM cells in vivo selectively home
to BM and liver and not to other organs. Moreover, we found that
5T2MM cells adhere selectively to BM, spleen and liver and not to
lung endothelial cells (Vanderkerken et al, 2000). In the present
study, we demonstrated that 5T2MM cells express 67LR and
migrate in vitro to LN and peptide 11. When radiolabelled
5T2MM cells were mixed with peptide 11 and co-injected into
syngeneic mice, the proportion of tumour cells which accumulated
in the BM after 18 hours was significantly decreased in peptide 11-
treated animals. This observation indicates that interaction
between 67LR and LN is at least partially involved in the in vivo
migration of 5T2MM cells through BM endothelium. Because of
Laminin-1-induced migration of multiple myeloma cells 1393
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Figure 6 Effect of LN on the in vitro transendothelial migration of primary
MM cells. For transendothelial cell migration, TranswellR filters were coated
with bone marrow endothelial cells as described in Materials and Methods.
LN was added into lower wells at 50 µ g ml–1. As negative control, dilution
medium (RPMI) was added to lower wells. Freshly isolated myeloma plasma
cells from 2 patients (pt 3 and pt 5) were placed into upper wells, with or
without peptide 11 (50 µ g ml–1). Columns represent the percentage increase
of control migration 
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Figure 7 Effect of peptide 11 on the in vivo migration of 5T2 MM cells.
5T2MM cells were labeled with 51Cr, mixed with peptide 11 (2 mg ml–1) or
scrambled peptide 11 and injected intravenously into the tail vein of
syngeneic mice. After 18 hours, mice were killed; legs, ribs and vertebrae
were removed, subsequently rinsed in PBS and radioactivity was determined
by gamma counting. Control and treatment groups contained 8 mice. Each
column represents the mean percentage ± SD of total recovered radioactivity
in the bone marrow. The P value was calculated from the 2- sample 
t-test (*: statistically significant)the broad expression of LN in extracellular matrices throughout
the body, it is clear that this molecule itself can not be the only
factor that determines the specificity of MM cell homing. It can be
assumed that several adhesion mechanisms and chemotactic
signals co-act to enhance the selectivity of tumour cell migration.
Moreover, the restricted localisation of MM cells in the BM might
also relate to the presence of a unique combination of growth and
survival factors, which is not available at other tissue sites. In
conclusion, we demonstrated that MM cells express the high-
affinity 67 kD LN receptor and that this receptor is involved in
LN-mediated cell migration. It is likely that 67LR is involved
during the extravasation of MM cells to the bone marrow. The
homing of myeloma cells to the bone marrow is believed to be a
multistep process, involving the action of various adhesion mole-
cules, chemotactic signals and metalloproteases. Interference with
one of the key steps in this process (like migration to laminin)
might be an important therapeutical tool to reduce tumour dissem-
ination. 
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